Fungus in humans identified for first time as key factor in Crohn's disease
A fungus has been identified as a key factor in the development of Crohn's disease an international team of researchers has identified for the first time.
View ArticleIntelGenx and RedHill Biopharma Announce RIZAPORTR Commercialization Term...
SAINTLAURENT CANADA Marketwired 092116 IntelGenx Corp. TSX VENTURE IGXOTCQX IGXT and RedHill Biopharma Ltd. NASDAQ RDHLTASE RDHL today announced that they have entered into a binding term sheet...
View ArticleNew Protein Target Offers Hope for Crohn's Sufferers
Scientists from the Sanford Burnham Prebys Medical Discovery Institute SBP say they have identified promising new target for future drugs to treat inflammatory bowel disease IBD. Their study...
View ArticleEMA panel backs Janssen's Crohn's disease drug
The European Medicines Agency's Committee for Medicinal Products for Human Use has endorsed the approval of Janssen's Stelara More
View ArticleImmune Therapeutics Inc. Announces Appointments to its Medical and Clinical...
ORLANDO Fla. Sept. 21 2016 PRNewswireUSNewswire Immune Therapeutics Inc. a clinicalstage pharmaceutical company focused on the commercialization and development of the first affordable nontoxic...
View ArticleRedHill Biopharma and IntelGenx Announce RIZAPORTÂ Commercialization Term...
RIZAPORTÂÂ5 mg and 10 mg was granted marketing approval in Germany under the European Decentralized Procedure DCP This binding term sheet for the license of RIZAPORTÂÂin South Korea follows a recent...
View ArticleTiGenix Appoints Dr. June Almenoff to its Board of Directors
PRESS RELEASE TiGenix Appoints Dr. June Almenoff to its Board of Directors Leuven BELGIUM September 22 2016 0700h CET TiGenix NV Euronext Brussels TIG an advanced biopharmaceutical company focused on...
View ArticleCISCRP To Collaborate With Local Miami Health and Research Organizations to...
Free health education community event will be hosted at the Hyatt Regency Miami on Thursday October 20 from 4 to 7 p.m. This evening program will offer more than 15 health screenings including breast...
View ArticleGilead ends ulcerative colitis study due to futility
Gilead Sciences Inc. NASDAQGILD said it is stopping a Phase IIIII study of ulcerative colitis candidate GS5745 based on an interim futility analysis that showed "insufficient evidence of a treatment...
View ArticleKenneth Rainin Foundation Awards Over $3 Million to HighRisk High Reward...
OAKLAND Calif. Sept. 22 2016 PRNewswireUSNewswire &160;The Kenneth Rainin Foundation announced today that it has awarded more than $3 million for Inflammatory Bowel Disease IBD research through its...
View ArticleGilead ends trial of ulcerative colitis treatment notes Abzena
Abzena plc LONABZA has noted US pharma Gilead Sciences Inc NasdaqGILD decision to end the Phase IIIII clinical study of GS5745 in patients with ulcerative colitis. Abzena added the termination affects...
View ArticleNew Research Indicates Alzheimer's and Other Neurodegenerative Diseases Are...
NEW YORK Sept. 23 2016 PRNewswire &160;Alzheimer's cancer and other incurable diseases such as Parkinson's and dementia can be contagious according to researchers at the Human Microbiology...
View ArticleUse Of Takeda's Entyvio Fueled By Gastroenterologists Seeking Better Outcomes...
ZUG Switzerland Sept. 23 2016 PRNewswire &160;In a market long dominated by AbbVie's Humira and Janssen's Remicade practice patterns are shifting and novel pipeline agents will introduce a new...
View ArticleFDA approves Amjevita a biosimilar to Humira
SILVER SPRING Md. Sept. 23 2016 PRNewswireUSNewswire &160;The U.S. Food and Drug Administration today approved Amjevita&160;adalimumabatto as a biosimilar to Humira adalimumab for multiple...
View ArticleFDA Approves Amgen's AMJEVITA AdalimumabAtto For Treatment Of Seven...
THOUSAND OAKS Calif. Sept. 23 2016 PRNewswire &160;Amgen NASDAQAMGN today announced that the U.S. Food and Drug Administration FDA has approved AMJEVITA&8482; adalimumabatto across all eligible...
View ArticleFDA approves Amgen's biosimilar of Humira
FDA approved Amjevita adalimumabatto ABP 501 from Amgen Inc. NASDAQAMGN a biosimilar of Humira adalimumab from AbbVie Inc. NASDAQABBV. The agency approved Amjevita for all indications Amgen had sought...
View ArticleFDA approves lowercost alternative to biotech drug Humira
Federal regulators on Friday approved the first alternative version of the secondbest selling drug in the world Humira the blockbuster injection used to treat rheumatoid arthritis and other...
View ArticleEndoscopic improvements with filgotinib are consistent with clinical...
MECHELEN Belgium Sept. 25 2016 GLOBE NEWSWIRE Galapagos NV Euronext & NASDAQ GLPG reports that Dr Severine Vermeire principal investigator of the FITZROY Phase 2 study with investigational...
View ArticleGalapagos NV Endoscopic improvements with filgotinib are consistent with...
Conference call 26 September at 14.00 CET8 AM ET 32 2 400 6926 code 8889838 Mechelen Belgium; 26 September 2016 02.00 CET Galapagos NV Euronext & NASDAQ GLPG reports that Dr Severine Ver...
View ArticleEndoscopic improvements with filgotinib are consistent with clinical...
ÂConference call 26 September at 14.00 CET8 AM ETÂ 32 2 400 6926 code 8889838 Mechelen Belgium; 26 September 2016 02.00 CET Galapagos NV Euronext & NASDAQ GLPG reports that Dr Severine Vermeire...
View Article